Displaying items by tag: division of pulmonary allergy and critical care medicine

A diabetes drug suggests potential therapy for idiopathic pulmonary fibrosis, based on research with human lung fibroblasts and a mouse model of lung fibrosis.
One-way valves that control air flow in the lungs have been shown to be effective in improving breathing for emphysema patients.
ECMO and autoantibody reduction through plasma exchange, experimental therapies not available everywhere, help end an Alabama woman’s five-month medical ordeal.
A two-drug combination therapy for cystic fibrosis is shown to be effective. Triple combination therapy is close behind.
Do you know the warning signs of sepsis? Most Americans don’t … and they should.
A new UAB study will investigate the role of autoantibodies and the benefit of therapeutic plasma exchange on a deadly lung disease.
A UAB physician will co-chair a steering committee of global cystic fibrosis experts and clinical trial investigators to support the design, conduct and execution of the triple combination pivotal study program.
Successful Phase III trials at UAB contributed to the development of a novel “corrector-potentiator” combination drug therapy for cystic fibrosis patients.
As lung diseases worsen worldwide, UAB has launched a pre-doctoral training program in pulmonary research that will focus on lung diseases such as asthma, cancer, COPD, cystic fibrosis, pneumonia, lung injury and idiopathic pulmonary fibrosis.
UAB’s Jack Hasson has been named the 2017 Outstanding Clinician by the American Thoracic Society.
Three UAB investigators have received innovative research grants for lung diseases from the National Institutes of Health.
UAB’s Mark Dransfield has been elected to the American Society for Clinical Investigation, an honor society for physician-scientists who have made significant contributions to better understanding of human disease.
UAB has created the only comprehensive interventional pulmonary medicine program in Alabama to better diagnose and treat lung and chest diseases.
In another example of precision medicine, UAB researchers have used IPF patients own lung tissue to create models to determine the most effective medication for that patient.
A new national, multisite study, chaired by a UAB pulmonologist, shows that supplemental oxygen does not reduce mortality or hospitalization for COPD patients with moderately low levels of blood oxygen.

Exacerbations of COPD, particularly mild COPD, lead to a decline in lung function in smokers, according to new research from UAB.

Page 4 of 6